Novartis Further Diversifies With Investment In Alcon

Swiss pharmaceutical giant Novartis is set to acquire an US$11bn stake in the ophthalmic group Alcon from Nestlé. Novartis has announced that it will acquire 25% of Alcon for US$143.18 per share. The acquisition appears go against the trend of its rival pharmaceutical companies, which are generally going back to basics and focusing on core

To read the full article, please choose one of the following options: